While our data show TGF-β induces a favorable memory phenotype in γδ T cells with enhanced in vivo persistence and anti-tumor activity, as mentioned above, this does come at the cost of combining this therapy with a monoclonal antibody, due to the lack of CD16 expression. This evidence concerns the gene TGFB1 and neoplasm.